Literature DB >> 17306645

Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment.

Andrea J Rapkin1.   

Abstract

OBJECTIVE: The decline in concentrations of gonadal hormones during menopause gives rise to a range of physiologic and psychologic changes that may impact a woman's health and quality of life significantly. Most notable among these are vasomotor symptoms (hot flashes and night sweats) and mood and sleep disturbances. STUDY
DESIGN: This article reviews the physiologic condition underlying menopausal vasomotor symptoms and centrally active, nonhormonal therapies that have demonstrated efficacy for their treatment.
RESULTS: Despite the emergence of a range of nonhormonal treatments for vasomotor symptoms, a need still exists for safe and effective therapeutic options that directly target the underlying thermoregulatory mechanisms for women who want treatment but prefer to avoid hormone therapy or for whom hormone therapy is contraindicated.
CONCLUSION: The availability of centrally active therapies for menopausal vasomotor symptoms with risks and benefits clearly defined by results from well-designed clinical trials has the potential to allay safety concerns that are associated with the treatment of these common symptoms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17306645     DOI: 10.1016/j.ajog.2006.05.056

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  29 in total

Review 1.  Black cohosh for the management of menopausal symptoms : a systematic review of clinical trials.

Authors:  Carlos Palacio; Ghania Masri; Arshag D Mooradian
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 2.  Diverse actions of estradiol on anorexigenic and orexigenic hypothalamic arcuate neurons.

Authors:  Todd L Stincic; Oline K Rønnekleiv; Martin J Kelly
Journal:  Horm Behav       Date:  2018-04-21       Impact factor: 3.587

3.  Modulation of higher-primate adrenal androgen secretion with estrogen-alone or estrogen-plus-progesterone intervention.

Authors:  Alan J Conley; Frank Z Stanczyk; John H Morrison; Pawel Borowicz; Kurt Benirschke; Nancy A Gee; Bill L Lasley
Journal:  Menopause       Date:  2013-03       Impact factor: 2.953

Review 4.  Minireview: neural signaling of estradiol in the hypothalamus.

Authors:  Martin J Kelly; Oline K Rønnekleiv
Journal:  Mol Endocrinol       Date:  2015-03-09

5.  Hormone therapy discontinuation: physician practices after the Women's Health Initiative.

Authors:  Katherine M Newton; Susan D Reed; Louis C Grothaus; Andrea Z La Croix; Larissa Nekhlyudov; Kelly Ehrlich; Evette J Ludman
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

6.  Treatment of Insomnia, Insomnia Symptoms, and Obstructive Sleep Apnea During and After Menopause: Therapeutic Approaches.

Authors:  Joshua Z Tal; Sooyeon A Suh; Claire L Dowdle; Sara Nowakowski
Journal:  Curr Psychiatry Rev       Date:  2015

7.  Contribution of a membrane estrogen receptor to the estrogenic regulation of body temperature and energy homeostasis.

Authors:  Troy A Roepke; Martha A Bosch; Elizabeth A Rick; Benjamin Lee; Edward J Wagner; Dana Seidlova-Wuttke; Wolfgang Wuttke; Thomas S Scanlan; Oline K Rønnekleiv; Martin J Kelly
Journal:  Endocrinology       Date:  2010-08-04       Impact factor: 4.736

8.  Menopause in German and Chinese women--an analysis of symptoms, TCM-diagnosis and hormone status.

Authors:  Thomas Rampp; Linda Tan; Lin Zhang; Zhuo-Jun Sun; Petra Klose; Frauke Musial; Gustav Jürgen Dobos
Journal:  Chin J Integr Med       Date:  2008-10-14       Impact factor: 1.978

Review 9.  A selective membrane estrogen receptor agonist maintains autonomic functions in hypoestrogenic states.

Authors:  Martin J Kelly; Oline K Rønnekleiv
Journal:  Brain Res       Date:  2013-03-25       Impact factor: 3.252

Review 10.  Actual status of veralipride use.

Authors:  Sebastián Carranza-Lira
Journal:  Clin Interv Aging       Date:  2010-09-07       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.